Lift of Stay Disallowed by District Court Post-SAS in View of PTAB’s Final Written Decision Lacking Non-Instituted Claims

Jun 18, 2018

Reading Time : 2 min

On July 29, 2015, DermaFocus LLC—a non-practicing entity—filed suit against Ulthera, Inc. in the District of Delaware alleging that the Ulthera infringed U.S. Patent No. 6,113,559 (the “’559 patent”) relating to a method and apparatus for therapeutic treatment of skin with ultrasound. Just shy of one year after DermaFocus’s complaint (on July 19, 2016), Ulthera filed an IPR challenging all claims of the ’559 patent. On November 11, 2016 the parties agreed to stay the district court litigation until the PTAB denied institution or issued a final written decision. Ultimately, the PTAB instituted IPRs on 16 of 18 claims and, on January 19, 2018, issued a final written decision rejecting all of Ulthera’s validity challenges. Consequently, DermaFocus moved to lift the stay.

Courts typically consider three factors when determining whether to stay, or lift a stay, in district court: (1) whether the stay will simplify the issues for trial; (2) the status of the litigation; and (3) whether the nonmoving party will be prejudiced—based on timing, delay, and the relationship of the parties. DermaFocus’s arguments to lift the stay centered on the more than two-year delay in litigation and the fact that the stay’s purpose had been fulfilled following the PTAB’s final written decision finding that all 16 instituted claims were patentable. Ulthera opposed the motion to lift the stay and instead sought a continuation based on its appeal to the Federal Circuit.

Although the aforementioned three factors normally govern motions to stay, Magistrate Judge Fallon determined that the SAS Institute decision mandated a different outcome. In SAS Institute, the Supreme Court ruled against the PTAB’s practice of partial institutions and held that the PTAB must issue final written decisions “with respect to patentability of any patent claim challenged” and that, in this context, “‘any’ means ‘every.’”

In the parallel IPR proceeding, the PTAB had instituted IPR on only 16 of the patent’s 18 claims. Accordingly, following the Supreme Court’s decision, Ulthera had filed a motion with the Federal Circuit requesting remand of the appeal to the PTAB for issuance of a final decision regarding patentability of the two claims not instituted. The Federal Circuit granted Ulthera’s remand motion and stated that the PTAB had “to resolve the patentability of all challenged claims in the pending IPR proceeding.”

As such, Magistrate Judge Fallon ruled that the parties’ stay agreement had not been fulfilled—specifically, the stipulation that the stay would be lifted “pending resolution by the PTAB of the patentability of all challenged claims in the pending IPR.” The motion to lift the stay was, therefore, denied because the conditions for originally implementing the stay still existed:  the PTAB had not finished considering all challenged claims in light of the SAS Institute decision.

DermaFocus LLC v. Ulthera, Inc., 1-15-cv-00654 (D. Del. June 7, 2018) (Fallon, MJ) (order denying motion to lift stay)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.